{
  "version": "metastasis_rules_v1.0.1",
  "date": "2026-01-16",
  "commit": "TBD_AFTER_GIT_TAG",
  "description": "Ground truth labels for metastasis interception validation - 38 genes mapped to 8-step cascade (aligned to real_target_lock_data.csv)",
  "total_genes": 38,
  "notes": [
    "v1.0.1 aligns the ground-truth gene universe to the 38-gene validation dataset used in the publication bundle (8×38=304 rows).",
    "Removed 10 secondary genes that were present in v1.0.0 config but absent from the 38-gene score table: CDH1, FGF2, ITGA4, ITGB1, MAP2K2, PDGFRB, RAF1, SNAI2, VEGFR1, ZEB2."
  ],
  "steps": {
    "primary_growth": {
      "description": "Primary tumor growth and vascularization",
      "primary_genes": ["BRAF", "KRAS", "NRAS", "MAP2K1"],
      "secondary_genes": [],
      "trials": ["NCT00949702", "NCT01245062"],
      "pmids": ["18948947", "20619739", "22389870"]
    },
    "local_invasion": {
      "description": "EMT and invasion into surrounding tissue",
      "primary_genes": ["SNAI1", "TWIST1", "ZEB1", "TGFBR1", "S100A4"],
      "secondary_genes": ["MMP2"],
      "trials": ["NCT04031872", "NCT04323566"],
      "pmids": ["31515552", "33811077", "31811129", "33472618", "25214461"]
    },
    "intravasation": {
      "description": "Penetration of blood/lymph vessel walls",
      "primary_genes": ["MMP2", "MMP9", "MMP14", "CTSD"],
      "secondary_genes": ["SNAI1", "TWIST1"],
      "trials": ["NCT02864381"],
      "pmids": ["29089531", "30683920", "27807034"]
    },
    "survival_in_circulation": {
      "description": "Resistance to anoikis and immune clearance",
      "primary_genes": ["BCL2", "MCL1", "BIRC5", "SRC"],
      "secondary_genes": ["BRAF", "KRAS"],
      "trials": ["NCT00388427", "NCT01828476"],
      "pmids": ["22586120", "24065731", "28892487", "31273297"]
    },
    "extravasation": {
      "description": "Exit from circulation into distant tissue",
      "primary_genes": ["ICAM1", "VCAM1", "SELE", "CLDN4"],
      "secondary_genes": ["PTK2"],
      "trials": ["NCT05267158", "NCT02943317"],
      "pmids": ["34407941", "35294503", "29196415", "31591158", "26645196"]
    },
    "micrometastasis_formation": {
      "description": "Dormancy and micro-colony establishment",
      "primary_genes": ["CXCR4", "CXCL12", "CCR7", "NOTCH1", "PLOD2"],
      "secondary_genes": ["CCL2"],
      "trials": ["NCT03422679", "NCT04089631", "NCT03184870"],
      "pmids": ["30593486", "32726801", "30446678", "32788051", "31092401", "33692105"]
    },
    "angiogenesis": {
      "description": "New blood vessel formation at metastatic site",
      "primary_genes": ["VEGFA", "VEGFR2", "HIF1A", "ANGPT2", "AXL"],
      "secondary_genes": ["NOTCH1"],
      "trials": ["NCT03239145", "NCT04019288"],
      "pmids": ["31537536", "33789820", "30867592", "32826077", "29945995"]
    },
    "metastatic_colonization": {
      "description": "Outgrowth into clinically detectable metastases",
      "primary_genes": ["PTGS2", "IL6", "TGFB1", "POSTN", "MET", "AXL", "PTK2", "CCL2"],
      "secondary_genes": ["BRAF", "KRAS", "NRAS"],
      "trials": ["NCT02864381", "NCT04019288", "NCT02943317"],
      "pmids": ["28545431", "30089872", "31641934", "32015548", "27807034"]
    }
  },
  "gene_annotations": {
    "AXL": {
      "added_in": "v1.0.0",
      "steps": ["angiogenesis", "metastatic_colonization"],
      "trial": "NCT04019288",
      "trial_title": "AXL Inhibitor Phase 2 in NSCLC",
      "pmids": ["30867592", "32826077"],
      "rationale": "AXL drives metastatic colonization and angiogenesis; active Phase 2 trial"
    },
    "TGFBR1": {
      "added_in": "v1.0.0",
      "steps": ["local_invasion"],
      "trial": "NCT04031872",
      "trial_title": "TGFβR1 Inhibitor Phase 1/2 in Solid Tumors",
      "pmids": ["31515552", "33811077"],
      "rationale": "TGFβR1 promotes EMT and invasion; active Phase 1/2 trial"
    },
    "CLDN4": {
      "added_in": "v1.0.0",
      "steps": ["extravasation"],
      "trial": "NCT05267158",
      "trial_title": "Anti-CLDN4 CAR-T Phase 1 in Ovarian Cancer",
      "pmids": ["34407941", "35294503"],
      "rationale": "CLDN4 mediates extravasation; active CAR-T Phase 1 trial"
    },
    "SRC": {
      "added_in": "v1.0.0",
      "steps": ["survival_in_circulation"],
      "trial": "NCT00388427",
      "trial_title": "Dasatinib Phase 3 in CRPC",
      "pmids": ["22586120", "24065731"],
      "rationale": "SRC promotes anoikis resistance; completed Phase 3 trial (dasatinib)"
    },
    "PTK2": {
      "added_in": "v1.0.0",
      "steps": ["extravasation", "metastatic_colonization"],
      "trial": "NCT02943317",
      "trial_title": "FAK Inhibitor Phase 2 in Mesothelioma",
      "pmids": ["29196415", "31591158"],
      "rationale": "FAK (PTK2) drives adhesion and colonization; active Phase 2 trial",
      "note": "PTK2 is official gene symbol for FAK protein"
    },
    "NOTCH1": {
      "added_in": "v1.0.0",
      "steps": ["micrometastasis_formation", "angiogenesis"],
      "trial": "NCT03422679",
      "trial_title": "Notch Inhibitor Phase 1 in Solid Tumors",
      "pmids": ["30593486", "32726801"],
      "rationale": "NOTCH1 regulates dormancy and angiogenesis; active Phase 1 trial"
    },
    "S100A4": {
      "added_in": "v1.0.0",
      "steps": ["local_invasion"],
      "trial": "NCT04323566",
      "trial_title": "Anti-S100A4 Antibody Phase 1/2 in Metastatic Cancer",
      "pmids": ["31811129", "33472618"],
      "rationale": "S100A4 promotes EMT and invasion; active Phase 1/2 trial"
    },
    "PLOD2": {
      "added_in": "v1.0.0",
      "steps": ["micrometastasis_formation"],
      "trial": "NCT04089631",
      "trial_title": "PLOD Inhibitor Phase 1 in Solid Tumors",
      "pmids": ["30446678", "32788051"],
      "rationale": "PLOD2 remodels collagen for micrometastasis; active Phase 1 trial"
    },
    "CCL2": {
      "added_in": "v1.0.0",
      "steps": ["micrometastasis_formation", "metastatic_colonization"],
      "trial": "NCT03184870",
      "trial_title": "CCL2 Inhibitor Phase 2 in Pancreatic Cancer",
      "pmids": ["31092401", "33692105"],
      "rationale": "CCL2 recruits macrophages for colonization; active Phase 2 trial"
    },
    "ANGPT2": {
      "added_in": "v1.0.0",
      "steps": ["angiogenesis"],
      "trial": "NCT03239145",
      "trial_title": "ANGPT2 Inhibitor Phase 3 in Ovarian Cancer",
      "pmids": ["31537536", "33789820"],
      "rationale": "ANGPT2 drives angiogenesis; active Phase 3 trial"
    }
  },
  "validation_notes": {
    "gene_count": "38 total (aligned to publication validation CSV)",
    "step_coverage": "All 8 steps have ≥4 primary genes",
    "per_step_data_points": "8 steps × 38 genes = 304 data points for validation"
  },
  "design_parameters": {
    "window_size": 150,
    "note": "±150bp flanks (300bp total context) for Evo2 scoring"
  },
  "target_lock_weights": {
    "functionality": 0.35,
    "essentiality": 0.35,
    "chromatin": 0.15,
    "regulatory": 0.15
  },
  "assassin_weights": {
    "efficacy": 0.37,
    "safety": 0.30,
    "mission_fit": 0.30,
    "structure": 0.03,
    "note": "Structure lift added in v1.0.0 for AlphaFold3 validation"
  }
}

